Merck KGaA, a leading science and technology company based in Darmstadt, Germany, has announced that the European Commission $(EC)$ has granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. This marks the first and only therapy approved in the European Union for treating desmoid tumors. The approval is a significant advancement for desmoid tumor patients and is based on the successful results of the Phase 3 DeFi trial, which demonstrated a substantial improvement in progression-free survival and objective response rate. The approval was issued to SpringWorks Therapeutics Inc., a healthcare company affiliated with Merck KGaA, underscoring their commitment to the rare tumor patient community.